Merck’s preliminary results for the Phase III study of rolofylline (MK-7418), an investigational medicine for the treatment of acute heart failure, shows that the drug did not meet the primary or secondary efficacy endpoints. The company will continue to analyze the data with outside experts, however it will not file applications for regulatory approval this year. Results from this study will be presented at a medical meeting later this year. The 2,033-patient Phase III study, PROTECT, ...